NCT05302583

Aromatherapy Inhaler Use for HSCT Distress

Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Detailed description

Phase 1: Transplant Day +1, +2, or +3. Phase 2: Washout Day: Standard of care (SOC) pharmacological intervention only. Phase 3: Transplant Day +3, +4, or +5). Study Completion: Transplant Day +4, +5, or +6. \*Study activities will occur on a single day for each phase. However, a three-day window for Phases 1 and 3 will allow consideration of patients' ability to participate in the immediate post-transplant period.

Conditions

• Cancer Distress
• Cancer Coping
• Hematopoetic Stem Cell Transplant
• Aromatherapy

Interventions

Type	Name	Description
OTHER	Aromatherapy Inhaler	Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler

Timeline

• Start date: 2025-06-16
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2022-03-31
• Last updated: 2026-04-13

Locations

1 site across 1 country: United States